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TRANSPLANTATION
Glutathione S-transferase M1 polymorphism: a risk factor for hepatic
venoocclusive disease in bone marrow transplantation
Alok Srivastava, Balasubramanian Poonkuzhali, Ramachandran V. Shaji, Biju George, Vikram Mathews,
Mammen Chandy, and Rajagopal Krishnamoorthy
Hepatic venoocclusive disease (HVOD) in
bone marrow transplantation (BMT) is
attributed to toxicity of cytoreductive
agents, especially busulfan and cyclo-
phosphamide, in the conditioning therapy.
Busulfan, as well as the metabolites of
cyclophosphamide, are conjugated with
glutathione (GSH), catalyzed by enzymes
of the glutathione S-transferase (GST)
family. To assess the impact of polymor-
phisms of the GST genes, GSTM1 and
GSTT1, on the risk of HVOD, we evaluated
114 consecutive patients with -thalasse-
mia major undergoing BMT. There was a
significantly increased incidence of HVOD
in patients with the GSTM1-null genotype
compared with those with the GSTM1-
positive genotype (46.5% vs 18.3%;
P  .001). Pharmacokinetic analysis in
these patients showed that the clearance
of busulfan was higher and first-dose
steady-state concentration was lower
among those with HVOD (0.403  0.06 vs
0.33 0.071 L/h/kg, Student t test P val-
ue .000 01; and 508  125 vs 656  255
ng/mL, t test P value  .001, respec-
tively). We conclude that the GSTM1-null
genotype predisposes to HVOD, and the
sinusoidal endothelial cells and hepato-
cyte damage may be mediated by metabo-
lites of busulfan through depletion of the
cellular GSH pool. (Blood. 2004;104:
1574-1577)
© 2004 by The American Society of Hematology
Introduction
Hepatic venoocclusive disease (HVOD) in patients undergoing
bone marrow transplantation (BMT) results from conditioning
therapy–related damage to the sinusoidal endothelial cells (SECs)
and the surrounding centrilobular hepatocytes,1,2 contributing to
significant treatment-related morbidity and mortality.3 The patho-
genesis of HVOD is not fully understood. Although age, sex,
cytomegalovirus (CMV) infection, and type of transplant4,5 have
been associated with this complication, cytotoxic drugs used in the
conditioning regimen are considered to be the most significant
causal factors for the development of HVOD.6,7 Low glutathione
(GSH) levels in hepatocytes (intrinsic or drug-induced) may
contribute to such cellular damage.8 Plasma levels of the cytoreduc-
tive agents commonly used in the conditioning regimen, busulfan
(Bu) and cyclophosphamide (Cy) and/or its metabolites, have been
associated with increased risk of HVOD.9,10 The association
between elevated Bu levels and HVOD has been attributed to
Bu-mediated depletion of hepatic GSH, which in turn predisposes
hepatocytes to injury from ensuing Cy exposure.11 Bu is metabo-
lized by the liver cytosolic glutathione S-transferases (GSTs) to
form a positively charged sulfonium ion that is cleaved to a
lipophilic compound, tetrahydrothiophene, which is also toxic to
SECs and hepatocytes.12 Whether Bu itself, the sulfonium ion, or
other metabolites are responsible for the toxicity is unclear.
GSTA1-1 is the predominant isoform of GST catalyzing the
conjugation of Bu with GSH, whereas GSTM1-1 and GSTP1-1
contribute 46% and 18% of the activity of GSTA1-1.13,14 Of the 4
main subfamilies of GST (A1, M1, T1, and P1), GSTM1 and
GSTT1 forms are known to be highly polymorphic with homozy-
gous deletion of either or both genes at varying but significant
frequencies in different ethnic groups.15,16 Cy is not directly toxic to
the SECs17; however, when metabolized by hepatic cytochrome
P450 enzymes, its metabolite, cyclophosphamide mustard, which
is a substrate for GSTA1-1,12 causes toxicity to the SECs.
Patients with thalassemia major undergoing BMT are particu-
larly prone to developing HVOD and the incidence can be as high
as 30% to 40%18,19 in those with significant pre-existing hepatic
damage. The aim of the present study was to assess whether the
polymorphisms of the GST genes are associated with the risk of
developing HVOD in this group of patients.
Patients, materials, and methods
Patients
All patients with -thalassemia major undergoing BMT at our center from
the year 1995 to 2002 were included in the analysis. Patients were
randomized to receive total Bu dose of 16 mg/kg or 600 mg/m2 in 4 divided
doses every day on days 9 to 6 and 50 mg/kg Cy intravenously once
daily on days5 to2. Antithymocyte globulin (30 mg/kg; Lymphoglobu-
line; Pasteur Meriuex, Paris, France) was given on days 4 to 2, only to
those receiving Bu at 16 mg/kg. All patients received 7.5 mg/kg phenytoin
orally in divided doses as prophylaxis against seizures, starting one day
before and stopping one day after Bu treatment. Informed consent was
obtained from the parents of all patients. The study was approved by the
Institutional Review Board of Christian Medical College (Vellore, India).
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Diagnosis of HVOD and analysis of potential
contributing factors
HVOD was diagnosed based on Baltimore criteria20 as follows: develop-
ment of hyperbilirubinemia with serum bilirubin level greater than 34.2 M
(2 mg/dL) with any 2 of the symptoms including ascites, painful hepato-
megaly, and unexplained weight gain of more than 5% from baseline within
20 days of BMT. Liver biopsies were not done for diagnosis of HVOD but
the liver was examined at autopsy in 2 patients who succumbed to HVOD.
Weight was recorded twice a day and liver function tests were assessed at
least twice a week in all patients. Age, serum bilirubin level, ferritin level,
aspartate aminotransferase (AST) level, alanine aminotransferase (ALT)
level, hepatitis B or C virus infection, and Lucarelli et al’s21 classification of
patients were correlated with the incidence of HVOD.
Busulfan assay and pharmacokinetic analysis
Bu levels in plasma samples were analyzed by a high-performance liquid
chromatography (HPLC) method using derivatization with tetrafluorothio-
phenol as previously reported.22 Pharmacokinetic analysis was done using
the TOPFIT program (Gustav Fischer, Stuttgart, Germany)23 as described
previously.18 Bu doses were not adjusted to achieve any predetermined
target level.
Assay of hepatic GSH
Glutathione levels in pre-BMT liver biopsy tissue homogenates were
measured by HPLC with fluorescent detection as described previously.24
Glutathione levels are expressed as nmol/mg protein.
Analysis of the GSTM1/T1 polymorphism
Genomic DNA from peripheral blood from all patients collected before
BMT and from 250 healthy controls was subjected to a multiplex
polymerase chain reaction (PCR) procedure reported earlier25 for simulta-
neous amplification of the GSTM1 and GSTT1 genes using albumin as the
internal control. The genotype assignment was made by electrophoretic
analysis of the amplified product in 2% agarose gel. This technique clearly
identifies the homozygous null genotype but does not discriminate the
deletional heterozygotes from nondeletional homozygotes, both of which
were classified as GSTM1-positive genotype.
Statistical analysis
Statistical significance of the difference between groups was calculated by
chi-square test, Fischer exact test, or Student t test as applicable. Crude odds
ratio (OR) was calculated with 95% confidence intervals. All statistical
analyses were performed using Epi Info statistical program (Centers for
Disease Control and Prevention, Atlanta, GA)26 and SPSS version 7.5
(Chicago, IL) for Windows. Multivariate logistic regression analysis was
done for the possible predictors of HVOD as independent variables.
Results
A total of 114 patients with -thalassemia major underwent BMT
during the period of this study. Their median age was 6 years
(range, 2-16 years). Pretransplantation risk stratification by Luca-
relli et al’s21 classification placed 9 patients in class I, 49 in class II,
and 56 in class III. The maximum weight gain and the highest
bilirubin level in the first 20 days after BMT are shown in Table 1.
All patients with HVOD had hepatomegaly more than 2 cm.
The maximum bilirubin level and the percentage weight gain
before day 20 was significantly higher in patients with HVOD
than those without HVOD (116.96  77.29 M vs 20.86  8.55
M [6.84  4.52 mg/dL vs 1.22  0.5 mg/dL]; P  .00001 and
14.2%  4.95% vs 3.6%  2.1%; P  .00001, respectively), and
this was also the case between those patients with GSTM1-null and
GSTM1-positive genotypes (bilirubin level 109.44 71.82 M vs
37.62  34.20 M [6.4  4.2 mg/dL vs 2.2  2 mg/dL]; P  .03;
weight gain 9.5%  7% vs 4.2%  4%; P  .01, respectively).
Pretransplantation bilirubin levels were similar between these 2
groups. There was a significantly higher incidence of HVOD in
patients with the GSTM1-null genotype compared with those with
the GSTM1-positive genotype (46.5% vs 18.3%; P  .001; Table
2). There was no significant difference in the incidence of HVOD
in patients with GSTT1-null or -positive genotype (18% vs 33.5%;
P  .13).
Of the 33 patients with HVOD, 8 had severe disease. Seven of
them died with HVOD as the major cause of death. Six (75%) of 8
of these patients had the GSTM1-null genotype. The GSTT1-null
genotype was seen in 6 (18%) of 33 patients with HVOD against 28
(35%) of 81 patients without HVOD.
The mean hepatic GSH levels in the pretransplantation liver
biopsy homogenates of 58 patients for whom the data were
available showed no significant difference between those with or
without HVOD (48.7  36 vs 40  35 nmol/mg protein; P  .38,
respectively).
The results of univariate and multivariate analysis of the known
risk factors of HVOD are given in Table 3. Of all the variables that
appeared significant on univariate analysis, only age and GSTM1
genotype turned out to be significant predictors of HVOD on
multivariate analysis.
The clearance (Cl/F) and steady-state concentration (Css) of
oral Bu after the first dose was significantly higher in thalassemic
patients who developed HVOD compared with those who did not
develop HVOD (0.403 0.06 vs 0.33 0.071 L/h/kg; P .00001
and 508  125 vs 656  255 ng/mL; P  .001, respectively).
When Bu Cl/F was included as one of the variables in multivariate
analysis, patients with a Cl/F above 0.37 L/h/Kg had a significantly
higher risk of developing HVOD compared with those with a Cl/F
below 0.37 L/h/Kg (OR, 4.1; P  .02). Further, patients with the
GSTM1-null genotype showed significantly higher Cl/F and lower
Css of Bu after the first dose compared with those with the
GSTM1-positive genotype (Table 4).
Table 1. Comparison of weight gain and bilirubin levels after BMT in
patients with and without HVOD
Maximum weight
gain, % (range)
Maximum bilirubin level,
M (range)
With HVOD 14.24  4.95 (6.3-27.5) 116.96  116.45 (37.62-506.16)
Without HVOD 4.67  3.8 (0-9.3) 21.03  9.41 (8.55-30.78)
P .00001 0.00001
The maximum weight gain and the highest bilirubin level in the first 20 days after
BMT are shown.
The conversion factor for serum bilirubin level is as follows: mg/dL 17.1 M.
Table 2. Frequency of GSTM1 and GSTT1 genotypes in patients
with and without HVOD
GSTM1 null,
n (%)
GSTM1 positive,
n (%)
GSTT1 null,
n (%)
GSTT1 positive,
n (%)
HVOD 23 (53.5) 58 (81.7) 28 (82) 53 (66.5)
HVOD 20 (46.5)* 13 (18.3)* 6 (18)† 27 (33.5)†
Numbers in each group are as follows: GSTM1 null, n 43; GSTM1 positive, n
71; GSTT1 null, n 34; and GSTT1 positive, n 80.
*P .001 by chi-square test.
†P .13 by chi-square test.
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Discussion
HVOD is a frequent complication of hematopoietic stem cell
transplantation,1,5 occurring at a frequency as high as 45% in those
with pre-existing liver dysfunction, as in patients with thalassemia
major.18,19 Various pretransplantation and transplantation-related
risk factors have been implicated in the pathogenesis of HVOD.
However, no single factor has so far been shown to be indepen-
dently significant. Our study in a large uniform cohort of patients
with -thalassemia major undergoing allogeneic BMT shows that
the incidence of HVOD is significantly higher in patients with the
GSTM1-null genotype compared with those with the GSTM1-
positive genotype.
The 2 main cytoreductive agents used in the conditioning
therapy for BMT, Bu and Cy, involve GST and GSH in their
metabolic pathway. The major route of detoxification of Bu is by
conjugation with GSH in the presence of GSTs and oxidation of the
resulting lipophilic metabolite, tetrahydrothiophene (THT), by
cytochrome P450 enzymes before excretion. On the other hand, Cy
is first biotransformed by the cytochrome P450 system to form the
active metabolite 4-hydroxy Cy, which requires GSH and GST for
further metabolism,11 making GST/GSH pool as a metabolic link
between these 2 drugs. This is consistent with the previous findings
that prior administration of Bu significantly altered exposure to
Cy.27 The observed increase in the incidence of HVOD in the
GSTM1-null patients may be due to altered metabolism of these
drugs, generating toxic metabolites that result in increased risk
of HVOD.
Multivariate logistic regression analysis of all the potential risk
factors of HVOD (age, serum bilirubin level, ferritin level, AST
level, ALT level, hepatitis B and C virus infections, and Lucarelli et
al’s classification of patients) revealed age and the GSTM1-null
genotype as the only significant predictors of HVOD (OR, 0.832;
P  .02; OR, 4.12; P  .0011). Age has previously been shown to
be a risk factor.3,4 Our data highlights the importance of GSTM1-
null status as a new and additional risk factor for HVOD.
To further explore the potential mechanisms that could explain
the association of the GSTM1 polymorphism with the elevated risk
of developing HVOD, we examined the correlation between Bu
pharmacokinetic parameters and HVOD. We found that the Cl/F of
oral Bu was significantly higher in thalassemic patients who
developed HVOD compared with those who did not develop
HVOD. Patients with Cl/F above 0.37 L/h/kg had a significantly
higher risk of developing HVOD compared with those below this
level (OR, 4.1; P  .02). Patients with the GSTM1-null genotype
showed significantly higher Cl/F and lower first-dose Css of Bu
compared with those with the GSTM1-positive genotype (Table 4).
This is also consistent with our earlier observation of significantly
increased incidence of HVOD in patients with lower Bu area under
the concentration versus time curve (AUC) and hence higher Bu
Cl/F.18 Based on these data, it is likely that HVOD results from
hepatocyte/SEC damage due to the metabolite of Bu (rather than
Bu itself) either directly or indirectly through depletion of the
cellular GSH pool. In fact, it has been suggested by DeLeve et al17
that hepatic toxicity of Bu could be due to either GSH depletion or
the GSH-conjugated metabolite of Bu, depending on the GSH
status of the cell. We did not find any difference in the pre-BMT
hepatic GSH levels in the liver in 58 patients with and without
HVOD for whom the data were available. It may be more
appropriate to assess postconditioning SEC/hepatic GSH levels and
their relationship with hepatic toxicity possibly in other models. It
is of interest to note that SECs are more vulnerable to GSH-
depleting drugs than hepatocytes, the latter being more efficient in
synthesizing GSH than SECs.28
For Bu Cl/F to be higher, elevated levels of GSTA1 would be
expected, as this is the major isoenzyme involved in the metabo-
lism of Bu.13,14 We have shown a 2- to 4-fold increase in the
enzyme and mRNA levels of GSTA1 in patients with -thalassemia
major with the GSTM1-null genotype compared with those with
the GSTM1-positive genotype.29 This would result in enhanced
metabolism of Bu and GSH depletion, thereby causing increased
toxicity in these patients. It has also been reported by Ritter et al30
that elevated expression levels of GSTA1-1 in patients treated with
Table 3. Pre-BMT characteristics of patients and their influence on the incidence of HVOD
With HVOD No HVOD
Univariate analysis Multivariate analysis
OR 95% CI P OR 95% CI P
Age, y, mean SD 9.58  4.6 6.52  3.8 0.844 0.76-0.94 .0014 0.832 0.71-0.98 .02
Serum bilirubin level, M,
mean SD 20.18  11.97 15.05  7.7 0.38 0.179-0.803 .0112 0.488 0.201-1.18 .112
Serum ferritin, ng/mL,
mean SD 3799  1728 3400  2095 0.999 0.99-1.0 .334 1.002 0.99-1.0 0.528
AST, U/L, mean SD 98  74 61  28 0.984 0.97-0.99 .0014 0.988 0.97-1.0 .143
ALT, U/L, mean SD 132  102 77  56 0.99 0.98-0.99 .0016 0.997 0.988-1.0 .52
Lucarelli, n
Class I 2 7 1.0 NA NA 1.0 NA NA
Class II 10 39 2.1 0.39-11 .38 2.246 0.28-17.6 .441
Class III 21 35 2.34 0.97-5.6 .058 2.062 0.22-19.54 .528
Hepatitis B/C infection, n 8 4 6.16 1.7-22.2 .0055 1.583 0.23-10.7 .34
GSTM1-null genotype, n 20 23 4.12 1.76-9.67 .0011 4.29 1.46-12.53 .0078
GSTT1-null genotype, n 6 28 0.421 0.155-1.14 .0884 0.563 0.163-1.94 .362
The conversion factor for serum bilirubin level is as follows: mg/dL 17.1 M.
NA indicates not applicable.
Table 4. Busulfan pharmacokinetic parameters with reference to
GSTM1 genotype
Css-1, ng/mL Cl/F-1, L/h/kg
GSTM1 null 544  184 0.40  0.064
GSTM1 positive 667  256 0.333  0.071
P* .001 .00001
Css-1 indicates steady-state concentration after the first dose of busulfan; and
Cl/F-1, clearance after the first dose of busulfan.
*P value calculated by 2-tailed t test.
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Bu could accelerate tissue factor expression due to injury to the
SECs, shifting these patients to a procoagulative state. They
postulated that variability in the expression of GST- could explain
the unpredictable occurrence of HVOD. Nevertheless, we cannot
exclude the possibility that the GST- enzyme encoded by the
GSTM1 locus could play a major role in hepatocytes/SEC protec-
tion, and its absence in individuals with the null genotype could be
detrimental to these cells.
McDonald et al10 have recently shown an association between
the AUC of Cy and its metabolites and the incidence of hepatic
toxicity. Our data clearly suggests that Bu or its metabolites cause
hepatic toxicity that may be worsened by subsequent exposure to
Cy, resulting in HVOD. It would be important to evaluate the
impact of Bu and Cy individually and sequentially on hepatic
expression of GST enzymes in animal models to define the role and
interaction of these drugs in causing hepatic/SEC toxicity.
The overall frequencies of the GSTM1- and GSTT1-null
genotypes in these patients were not significantly different from
those seen in the healthy controls (37.7% vs 33% had the
GSTM1-null genotype, 29% vs 26% had the GSTT1-null geno-
type, and 9.6% and 8% had both null genotypes among 114
thalassemic patients and 250 healthy controls, respectively), quite
similar to those reported for Asian Indian population,31,32 and the
frequency of the GSTM1-null genotype is lower than that has been
reported for another Caucasian population (33% vs 50%;
P  .003).16 Hence, the high incidence of the GSTM1-null geno-
type in thalassemic patients with HVOD cannot be attributed to
increased frequency of this genotype in the Indian population.
We conclude that the GSTM1-null genotype is an independent
risk factor for HVOD in patients with -thalassemia major
undergoing BMT. Its identification prior to BMT could allow
individualization of therapy with regard to conditioning regimen
and prophylaxis for HVOD.
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